Please assess the completion status of the following clinical trial:

Trial Title: Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18~2. Subject willing and able to give informed consent.~3. Adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.~4. PASI \> 10 and BSA affected with psoriasis \> 10.~5. Abdominal obesity defined by waist hip ratio \> 0.90 for men and \> 0.85 for women and BMI ³ 30 kg/m2~Exclusion Criteria:~* On insulin or other diabetes (anti-hyperglycemic) medication~* Congestive Heart Failure~* Heart Attack, Stroke or Transient Ischemic Attack in last 3 months~* Unstable angina~* Pulmonary disease requiring oxygen~* SLE, optic neuritis, transverse myelitis, epilepsy~* Positive PPD~* Scheduled for upcoming surgery~* Known immunosuppression (for example, HIV)~* Known autoimmune disease~* Hepatitis B or Hepatitis C~* Pregnant or nursing~* Renal insufficiency (Creatinine \>1.5)~* Latex allergy~* Use of live vaccination in past 90 days~* Organ transplantation~* History of severe infection~* History of malignancy (except cured non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): Etanercept

Based on this trial design, predict the completion outcome and termination type (if applicable).